Multicentre proton magnetic resonance spectroscopy imaging of primary progressive multiple sclerosis

Multiple Sclerosis

Volumn 10, Issue SUPPL. 1, 2004, Pages

  Narayana, Ponnada A ^a   Wolinsky, Jerry S ^a   Rao, Sajja B ^a   He, Renjie ^a   Mehta, Meghana ^a   Books, William ^b   Ford, Corey ^c   Richards, Todd ^d   Bowen, James ^d   William Lindsey, J ^a   Boulanger, Yvan ^e   Duquette, Pierre ^e   Arnold, Douglas L ^f  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF KANSAS   (United States)

^c UNIVERSITY OF NEW MEXICO   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f MCGILL UNIVERSITY   (Canada)

Author keywords

MRI; N acetylaspartate; Primary progressive multiple sclerosis; Proton spectroscopic imaging

Indexed keywords

CREATINE; GLATIRAMER; LIPID; N ACETYLASPARTIC ACID;

ARTICLE; CLINICAL TRIAL; COMPUTER PROGRAM; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DIAGNOSTIC IMAGING; DISABILITY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; GRAY MATTER; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; METABOLITE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; PROTON NUCLEAR MAGNETIC RESONANCE; RATING SCALE; STATISTICAL SIGNIFICANCE; WHITE MATTER;

EID: 3042639536     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458504ms1035oa     Document Type: Article

References (26)

1. Lublin VD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907-11.
2. Thompson AJ, Kermode AG, MacManus DG, Kendall BE, Kingsley DP, Moseley IF, et al. Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. BMJ 1990; 300: 631-34.
3. Stevenson VL, Miller DH, Rovaris M, Barkhof F, Brochet B, Dousset V, et al. Primary and transitional progressive MS: a clinical and MRI cross-sectional study. Neurology 1999; 52: 839-45.
4. Filippi M, Iannucci G, Tortorella C, Minicucci L, Horsfield MA, Colombo B, et al. Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI. Neurology 1999; 52: 588-94.
5. Tortorella C, Viti B, Bozzali M, Sormani MP, Rizzo G, Gilardi MF, et al. A magnetization transfer histogram study of normal-appearing brain tissue in MS. Neurology 2000; 54: 186-93.
6. Rovaris M, Bozzali M, Santuccio G, Ghezzi A, Caputo D, Montanari E, et al. In vivo assessment of the brain and cervical cord pathology of patients with primary progressive multiple sclerosis. Brain 2001; 124: 2540-49.
7. Dehmeshki J, Chard DT, Leary SM, Watt HC, Silver NC, Tofts PS, et al. The normal appearing grey matter in primary progressive multiple sclerosis: a magnetisation transfer imaging study. J Neurol 2003; 250: 67-74.
8. Simmons ML, Frondoza CG, Coyle JT. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 1991; 45: 37-45.
9. Bitsch A, Bruhn H, Vougioukas V, Stringaris A, Lassmann H, Frahm J, et al. Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. AJNR Am J Neuroradiol 1999; 20: 1619-27.
10. Caramanos Z, Santos AC, Francis SJ, Narayanan S, Pelleetier D, Arnold DL. Proton magnetic resonance spectroscopy. In Filippi M, Comi G eds. Primary progressive multiple sclerosis. Milan: Springer Verlag, 2002: 89-112.
11. Bedell BJ, Narayana PA, Wolinsky JS. A dual approach for minimizing false lesion classifications on magnetic resonance images. Magn Reson Med 1997; 37: 94-102.
12. Kuhn B, Dreher W, Norris DG, Leibfritz D. Fast proton spectroscopic imaging employing k-space weighting achieved by variable repetition times. Magn Reson Med 1996; 35: 457-64.
13. Yu H, Narayana PA. Quantitative comparison of variable and constant repetition time proton spectroscopic imaging. Proceedings of the International Society for Magnetic Resonance in Medicine Eighth Scientific Meeting. Denver, CO, April 1-7, 2000: 427.
14. Doyle TJ, Pathak R, Wolinsky JS, Narayana PA. Automated proton spectroscopic image processing. J Magn Reson B 1995; 106: 58-63.
15. Marion D, Ikura M, Bax A. Improved solvent suppression in one-dimensional and two-dimensional NMR-spectra by convolution of time-domain data. J Magn Reson 1989; 84: 425-30.
16. Marshall I, Bruce SD, Higinbotham J, MacLullich A, Wardlaw JM, Ferguson KJ, et al. Choice of spectroscopic lineshape model affects metabolite peak areas and area ratios. Magn Reson Med 2000; 44: 646-49.
17. De Stefano, Narayanan S, Francis GS, Arnaoutelis R, Tartaglia MC, Antel JP, et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 2001; 58: 65-70.
18. Narayana PA, Doyle TJ, Lai D, Wolinsky JS. Serial proton magnetic resonance spectroscopic imaging, contrast enhanced magnetic resonance imaging and quantitative lesion volumetry in multiple sclerosis. Ann Neurol 1998; 43: 56-71.
19. He R, Narayana PA. Automatic delineation of Gd enhancements on magnetic resonance images in multiple sclerosis. Med Phys 2002; 29: 1536-46.
20. Zar JH. Biostatistical analysis. Englewood Cliffs, NJ: Prentice Hall, 1984: 168.
21. Webb PG, Sailasuta N, Kohler SJ, Raidy T, Moats RA, Hurd RE. Automated single-voxel proton MRS: technical development and multisite verification. Magn Reson Med 1994; 31: 365-73.
22. Leary SM, Davie CA, Parker GJM, Stevenson VL, Wang L, Barker GJ, et al. 1H magnetic resonance spectroscopy of normal appearing white matter in primary progressive multiple sclerosis. J Neurol 1999; 246: 1023-26.
23. Filippi M, Rovaris M, Gasperini C, Capra R, Bastianello S, Kuhne I, et al. A preliminary study comparing the sensitivity of serial monthly enhanced MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in primary progressive multiple sclerosis. J Neuroimaging 1998; 8: 88-93.
24. Wolinsky JS, Narayana PA. MR spectroscopy in MS: window into the diseased brain. Curr Opin Neurol 2002; 15: 247-51.
25. Sharma R, Narayana PA, Wolinsky JS. Grey matter abnormalities in multiple sclerosis: proton magnetic resonance spectroscopic imaging. Mult Scler 2001; 7: 221-26.
26. Filippi M, Rocca MA, Falini A, Caputo D, Ghezzi A, Colombo B, et al. Correlations between structural CNS damage and functional MRI changes in primary progressive MS. Neuroimage 2002; 15: 537-46.